Redirecting lentiviral vectors by insertion of integrin-tageting peptides into envelope proteins

Journal of Gene Medicine

Volumn 11, Issue 7, 2009, Pages 549-558

  Morizono, Kouki ^a   Pariente, Nonia ^a   Xie, Yiming ^a   Chen, Irvin S Yu ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Integrin; Lentiviral vector; RGD peptide; Sindbis virus envelope; Targeting vector

Indexed keywords

ENVELOPE PROTEIN; INTEGRIN; LENTIVIRUS VECTOR; HYBRID PROTEIN; PEPTIDE; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DISULFIDE BOND; DRUG SYNTHESIS; FEASIBILITY STUDY; FLOW CYTOMETRY; GENE INSERTION; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN STRUCTURE; SINDBIS VIRUS; SITE DIRECTED MUTAGENESIS; ULTRACENTRIFUGATION; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTIVITY; VIRUS TITRATION; ANIMAL; CELL LINE; GENE VECTOR; GENETICS; LENTIVIRINAE; METABOLISM;

ANIMALIA; SINDBIS VIRUS;

ANIMALS; CELL LINE; GENETIC VECTORS; HUMANS; INTEGRINS; LENTIVIRUS; PEPTIDES; RECOMBINANT FUSION PROTEINS; SINDBIS VIRUS; TRANSDUCTION, GENETIC; VIRAL ENVELOPE PROTEINS;

EID: 68949220821     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1339     Document Type: Article

References (42)

1. Amado RG, Chen IS. Lentiviral vectors - the promise of gene therapy within reach? Science 1999; 285: 674-676.
2. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672.
3. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410-2413.
4. Akporiaye ET, Hersh E. Clinical aspects of intratumoral gene therapy. Curr Opin Mol Ther 1999; 1: 443-453.
5. Follenzi A, Battaglia M, Lombardo A, et al. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood 2004; 103: 3700-3709.
6. Brown BD, Cantore A, Annoni A, et al. A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood 2007; 110: 4144-4152.
7. Brown BD, Sitia G, Annoni A, et al. In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood 2007; 109: 2797-2805.
8. Brown BD, Venneri MA, Zingale A, et al. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 2006; 12: 585-591.
9. De Palma M, Venneri MA, Roca C, et al. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 2003; 9: 789-795.
10. Bushman F, Lewinski M, Ciuffi A, et al. Genome-wide analysis of retroviral DNA integration. Nat Rev Microbiol 2005; 3: 848-858.
11. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007; 8: 573-587.
12. Boerger AL, Snitkovsky S, Young JA. Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types. Proc Natl Acad Sci USA 1999; 96: 9867-9872.
13. Roux P, Jeanteur P, Piechaczyk M. A versatile and potentially general approach to the targeting of specific cell types by retroviruses: application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses. Proc Natl Acad Sci USA 1989; 86: 9079-9083.
14. Bupp K, Roth MJ. Targeting a retroviral vector in the absence of a known cell-targeting ligand. Hum Gene Ther 2003; 14: 1557-1564.
15. Funke S, Maisner A, Muhlebach MD, et al. Targeted cell entry of lentiviral vectors. Mol Ther 2008; 16: 1427-1436.
16. Kasahara N, Dozy AM, Kan YW. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 1994; 266: 1373-1376.
17. Marin M, Noel D, Valsesia-Wittman S, et al. Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins. J Virol 1996; 70: 2957-2962.
18. Martin F, Chowdhury S, Neil S, et al. Envelope-targeted retrovirus vectors transduce melanoma xenografts but not spleen or liver. Mol Ther 2002; 5: 269-274.
19. Nilson BH, Morling FJ, Cosset FL, et al. Targeting of retroviral vectors through protease-substrate interactions. Gene Ther 1996; 3: 280-286.
20. Somia NV, Zoppe M, Verma IM. Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. Proc Natl Acad Sci USA 1995; 92: 7570-7574.
21. Valsesia-Wittmann S, Drynda A, Deleage G, et al. Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J Virol 1994; 68: 4609-4619.
22. Morizono K, Bristol G, Xie YM, et al. Antibody-directed targeting of retroviral vectors via cell surface antigens. J Virol 2001; 75: 8016-8020.
23. Morizono K, Ringpis GE, Pariente N, et al. Transient low pH treatment enhances infection of lentiviral vector pseudotypes with a targeting Sindbis envelope. Virology 2006; 355: 71-81.
24. Morizono K, Xie Y, Ringpis GE, et al. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med 2005; 11: 346-352.
25. Pariente N, Mao SH, Morizono K, et al. Efficient targeted transduction of primary human endothelial cells with dual-targeted lentiviral vectors. J Gene Med 2008; 10: 242-248.
26. Pariente N, Morizono K, Virk MS, et al. A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration. Mol Ther 2007; 15: 1973-81.
27. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987; 238: 491-497.
28. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology 1995; 13: 265-270.
29. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713.
30. Harui A, Roth MD, Vira D, et al. Adenoviral-encoded antigens are presented efficiently by a subset of dendritic cells expressing high levels of alpha(v)beta3 integrins. J Leukoc Biol 2006; 79: 1271-1278.
31. Shi W, Bartlett JS RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol Ther 2003; 7: 515-525.
32. Vigne E, Mahfouz I, Dedieu JF, et al. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol 1999; 73: 5156-5161.
33. Wickham TJ, Tzeng E, Shears LL II, et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997; 71: 8221-8229.
34. Klimstra WB, Williams JC, Ryman KD, et al. Targeting Sindbis virus-based vectors to Fc receptor-positive cell types. Virology 2005; 338: 9-21.
35. Klimstra WB, Heidner HW, Johnston RE. The furin protease cleavage recognition sequence of Sindbis virus PE2 can mediate virion attachment to cell surface heparan sulfate. J Virol 1999; 73: 6299-6306.
36. Cao Q, Li ZB, Chen K, et al. Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer. Eur J Nucl Med Mol Imaging 2008; 35: 1489-1498.
37. Dijkgraaf I, Rijnders AY, Soede A, et al. Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes. Org Biomol Chem 2007; 5: 935-944.
38. Mousa SA. Alpha v integrin affinity/specificity and antiangiogenesis effect of a novel tetraaza cyclic peptide derivative, SU015, in various species. J Cardiovasc Pharmacol 2005; 45: 462-467.
39. Thumshirn G, Hersel U, Goodman SL, et al. Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry 2003; 9: 2717-2725.
40. Stewart PL, Nemerow GR. Cell integrins: commonly used receptors for diverse viral pathogens. Trends Microbiol 2007; 15: 500-507.
41. Gao Y, Whitaker-Dowling P, Watkins SC, et al. Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line. J Virol 2006; 80: 8603-8612.
42. Aires da Silva F, Costa MJ, Corte-Real S, et al. Cell type-specific targeting with sindbis pseudotyped lentiviral vectors displaying anti-CCR5 single-chain antibodies. Hum Gene Ther 2005; 16: 223-234.